NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.392) was uploaded to the NHS England Website on Wednesday 1, April 2026.
The following changes have been introduced:
Ripretinib (RIP1)
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Vorasidenib (VOR1)
For treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in patients aged 12 years and over where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Belantamab mafodotin with pomalidomide and dexamethasone (BELA2)
Belantamab mafodotin with pomalidomide and dexamethasone as 2nd line treatment of relapsed or refractory myeloma in adult patients who previously received lenalidomide as part of 1st line systemic therapy where the following criteria have been met
Correction - Moved into section A of list; Date moving into routine commissioning updated
Niraparib (NIR3) ## Niraparib (NIR3)
Niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy AND who HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation [NICE TA673] where the following criteria have been met There is a separate form NIR4 for use of niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy and who DO NOT HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation Niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy AND who HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation (TA673) where the following criteria have been met There is a separate form NIR4 for use of niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy and who DO NOT HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation
Correction - Moved into section A of list; Date moving into routine commissioning updated Correction - Moved into section A of list; Date moving into routine commissioning updated
Niraparib (NIR3) ## Niraparib (NIR3)
Niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy AND who HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation [NICE TA673] where the following criteria have been met There is a separate form NIR4 for use of niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy and who DO NOT HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation Niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy AND who HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation (TA673) where the following criteria have been met There is a separate form NIR4 for use of niraparib monotherapy as maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy and who DO NOT HAVE a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation
Correction - Moved into section A of list; Date moving into routine commissioning updated Correction - Moved into section A of list; Date moving into routine commissioning updated
Talazoparib plus enzalutamide (TAL2)
For the treatment of metastatic hormone- relapsed (castrate-resistant) prostate cancer in patients who are treatment naïve to androgen receptor inhibitors and in whom chemotherapy is not yet clinically indicated or appropriate where the following criteria have been met
Correction - Moved into section A of list; Date moving into routine commissioning updated
NA (VEN7)
NA
Removed from section A
Venetoclax in combination with obinutuzumab (VEN6)
For the treatment of patients with previously untreated chronic lymphatic leukaemia which doesn’t have a 17p deletion or TP53 mutation where the following criteria have been met
Indication column updated; Several treatment criterion updated; combined with previous VEN7 form
Epcoritamab monotherapy (EPC2)
Epcoritamab monotherapy for previously treated adult patients with relapsed/refractory follicular lymphoma who have received 2 or more lines of systemic therapy where the following criteria have been met
Correction of Date moving into routine commissioning